Last reviewed · How we verify
NCT04075851
The Prevalence of Serum Thyroid Hormone Autoantibodies in Autoimmune Thyroid Diseases
trial in Autoimmune Thyroid Disease in 600 participants. Status unknown.
1 August 2022
Quick facts
| Lead sponsor | Shandong Provincial Hospital |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 600 |
| Start date | 1 August 2019 |
| Primary completion | 1 August 2022 |
| Estimated completion | 1 August 2022 |
| Sites | 1 location across China |
Conditions studied
- Autoimmune Thyroid Disease — all drugs for Autoimmune Thyroid Disease →
Sponsor
Shandong Provincial Hospital
Who can join
Adults 18 to 65, any sex, with Autoimmune Thyroid Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Thyroid hormone autoantibodies(THAA) in serum can Interfere radioimmunoassay for the determination of free thyroid hormones. Thyroid function test plays a key role in the diagnosis and treatment of autoimmune thyroid disease (AITD), and abnormal examination results in misdiagnosis and mistreatment. At present, the epidemiological results of THAA in AITD are inconsistent, and the pathogenesis has not been clarified. However, there is no relevant research on THAA in China. This project intends to collect AITD patients and healthy people, detecting THAA, at the same time testing thyroid function and thyroid autoantibodies, definiting positive rate of THAA in AITD patients, observing the effect of common therapeutic drugs for AITD on THAA, investigating the rule of THAA influencing thyroid function test results .This project will provide the basis and method for how to effectively avoid THAA interfering with thyroid function test.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Medical Applications of Molecular Biotechnologies in the Context of Hashimoto's Thyroiditis.
Trovato M, Valenti A. · · 2023 · cited 1× · PMID 37371008 · DOI 10.3390/diagnostics13122114
Verify or expand the search:
- PubMed search for NCT04075851
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Shandong Provincial Hospital trials
Trials by the same sponsor.
- NCT07333287 — A Multicenter Single-arm Prospective Clinical Study on First-line Treatment of Pancreatic Cancer Liver Metastases With A · Phase 2 · not yet recruiting
- NCT07180342 — An Empirical Study on the Mechanisms of Biopsychosocial Functional Improvement in Patients With Major Depressive Disorde · NA · recruiting
- NCT07284992 — SCRT VS LCRT Followed by PD-L1 Inhibitor Plus CAPEOX as TNT in Patients With LARC · Phase 2 · recruiting
- NCT06908382 — Neoadjuvant QL1706 Therapy for ESCC · Phase 2 · recruiting
- NCT06829797 — A Multicenter Randomized Controlled Phase II Trial of Iparomlimab and Tuvonralimab (QL1706) Combined with SOX Chemothera · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04075851 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Shandong Provincial Hospital
- Last refreshed: 14 April 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04075851.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing